Clinical Advisory PanelMinomic draws upon the expertise of five internationally esteemed medical experts on its Clinical Advisory Panel
Professor David Gillatt (Chair)
Macquarie University Hospital, Australia
David was a leading UK prostate cancer surgeon who is now both Professor of Urological Oncology and Robotic Surgery and Director of Medical Services at Macquarie University Hospital. He is recognised as one of the world’s foremost robotic surgeons in the treatment of both prostate and bladder cancers. He also has expertise in the discovery and optimisation of biomarkers for early prostate cancer.
Dr Neal Shore
Carolina Urologic Research Center and Atlantic Urology Clinics, USA
Neal is an internationally recognised clinical researcher, working on innovative therapies for patients suffering prostate enlargement in the USA. His extensive research has included more than 350 clinical studies mainly focused on prostate and bladder disease. He is a past President of LUGPA and Director of Carolina Urologic Research Centre and CMO Surgery/Urology, Genesis Healthcare.
Professor Daniel W. Chan
Johns Hopkins University and Johns Hopkins Hospital, USA
Daniel is the Director of The Center for Biomarker Discovery and Translation and Professor of Pathology, Oncology, Radiology and Urology at the Johns Hopkins University. He is also the Director of Clinical Chemistry Division and the Co-Director of Pathology Core Laboratory at the Johns Hopkins Hospital, Baltimore, USA.
Professor Mark Emberton, OBE
University College London, UK
Mark is Dean of the Faculty of Medical Science at University College London. He leads a clinical innovation team that majors in experimental medicine by combining bio-engineering and nanotechnology with early phase trials in men with prostate cancer.